Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
DiscussionForty-six percent of the patients in our Obesity Clinic have been diagnosed with prediabetes (32%) or diabetes (14%). The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors. This effect could be translated into less time before undergoing bariatric surgery and better control of associated comorbidities.Trial registrationClinicaltrials.gov, ID:NCT03968224. Retrospectively registered on May 29, 2019.
Source: Trials - Category: Research Source Type: clinical trials
More News: Bariatric Surgery | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Dapagliflozin | Diabetes | Eating Disorders & Weight Management | Endocrinology | Fortamet | Forxiga | Heart | Insulin | Metformin | Obesity | Research | Study | Weight Loss